When ARCSA announced that its electronic adverse event reporting system would enter operation in August 2027 under the ICH E2B(R3) standard, the industry's reaction across Latin America was predictable: two years feels like a long time. It isn't.
Migrating a legacy pharmacovigilance system to the E2B(R3) standard is not a software update. It's a restructuring of the entire data flow: how a case is captured, how it's structured, how it's coded, how it's transmitted, and how it's reconciled. Each of those steps has specific technical requirements that don't accept approximation.
I've watched up close what happens when a manufacturer arrives late to a regulatory change of this magnitude. The institutional response is almost always the same: put a translation layer on top of the existing system. Middleware that pulls data from the legacy system, reformats it to the new standard, and sends it to the authority. It works the first quarter. In the second, the first rejections appear for structural inconsistencies. In the third, the authority starts asking more specific questions. In the fourth, the legacy system can't answer those questions, and the manufacturer discovers the translation layer wasn't enough.
The option the industry isn't considering
The alternative is building the E2B(R3)-native system from design. Not adapt, build. Every field, every validation, every flow, every cross-check designed for the 2027 standard from day one. The reason very few manufacturers are taking this route is because it means replacing pharmacovigilance infrastructure that cost millions and took years to implement.
For a consortium of manufacturers operating in Latin America under a regional pharmacovigilance provider, that logic changes. A regional provider can build new infrastructure once, and offer it as a service to dozens of clients simultaneously. The economics work at that scale; they don't work at the level of an individual manufacturer.
What we're building
Our pharmacovigilance system enters operation January 2027 — nine months before ARCSA's deadline. It was built AI-native from design, with automation as a structural component, not a cosmetic layer. Assisted case processing, automated regional literature monitoring, quarterly ICSR reconciliation with cross-market validation, and E2B(R3) reporting without intermediate transformation.
The system covers all eight IRIS network markets under a single contract. Local QPPV in each country, 24/7 contact with regulatory authorities, case management under the same regional methodology. This is not a future promise. It's infrastructure that exists and is in final validation before formal launch.
Why this matters for the manufacturer who already has a system
If you have a pharmacovigilance system operating in the region today and you're evaluating whether it can migrate to the 2027 standard without compromising compliance during the transition, three questions are worth asking:
First: does the system capture the data required by E2B(R3) at the point of origin, or derive it from existing fields? Legacy systems typically derive. E2B(R3)-native systems capture directly.
Second: is cross-market reconciliation automatic or manual? With eight Latin American regulatory authorities migrating to the same standard in a 24-month cycle, manual reconciliation becomes the most common failure point.
Third: does the provider have audit precedent under the new standard, or only under the previous one? Precedent matters because Latin American regulatory authorities are already practicing inspections under E2B(R3) criteria in preparation for August 2027.
If all three answers are "yes, it's E2B(R3)-native, yes it's automatic, yes there's audit precedent under the new standard," the manufacturer's current system is probably fine. If any answer is "no" or "in development," it's worth a conversation before the deadline gets closer.
